The major current conventional types of metastatic breast cancer (MBC) treatments include
surgery, radiation, hormonal therapy, chemotherapy, or immunotherapy. Introducing …

Triple-negative breast cancer (TNBC), which accounts for 15–20% of all breast cancers,
does not express estrogen receptor (ER) or progesterone receptor (PR) and lacks human …

Background Treatment options for women presenting with triple negative breast cancer
(TNBC) are limited due to the lack of a therapeutic target and as a result, are managed with …

Theranostics has emerged in recent years to provide an efficient and safer alternative in
cancer management. This review presents an updated description of nanotheranostic …

Epidemiologic studies have contributed importantly to current knowledge of environmental
and genetic risk factors for breast cancer. Worldwide, breast cancer is an important cause of …

Triple-negative breast cancer (TNBC) is a subtype of breast tumor with unique
characteristics in terms of clinical− pathological presentation, prognosis, and response to …

Breast cancer (BC) is the second most common cause of cancer deaths. Triple‐negative
breast cancer (TNBC) does not show immunohistochemical expression of oestrogen …

How breast diversity is generated is a fascinating and fundamental question with important
clinical implications. It is clear that the diversity of phenotypes displayed by breast cancer …

Triple-negative breast cancer (TNBC) is characterized by a high degree of immune infiltrate
in the tumour microenvironment, which may influence the fate of TNBC cells. We reveal that …

Personalized medicine promises to revolutionize cancer therapy by matching the most
effective treatment to the individual patient. Using a nanoparticle-based system, we predict …